Buy this Article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Authors

  1. Aschenbrenner, Diane S. MS, APRN, BC

Abstract

* The FDA has approved the new drug rufinamide (Banzel) for adjunctive use in the treatment of Lennox-Gastaut syndrome, a rare and severe form of epilepsy.

 

* The most common adverse effects include somnolence, fatigue, ataxia and disturbance of gait, dizziness, nausea, vomiting, and blurred or double vision.